10/7/2008

Crucell announced that it secured a contract worth as much as $70 million from the National Institute of Allergy and Infectious Diseases to develop vaccines for the Ebola and Marburg viruses, which are responsible for hemorrhagic fever. The Dutch biotech firm said it will work with the Southwest Foundation for Biomedical Research in San Antonio and Quintiles Guy's Drug Research Unit in London for the project.

Related Summaries